IL-33 in rheumatoid arthritis: Potential role in pathogenesis and therapy

Human Immunology

Volumn 74, Issue 9, 2013, Pages 1057-1060

  Xu, Wang Dong ^a   Zhang, Min ^a   Zhang, Yu Jing ^a   Ye, Dong Qing ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 33; INTERLEUKIN 5;

AUTOIMMUNE DISEASE; BONE DESTRUCTION; BONE EROSION; ENTERITIS; FIBROBLAST; HUMAN; IMMUNOREGULATION; MYOFIBROBLAST; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PATHOGENESIS; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RHEUMATOID ARTHRITIS;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; IMMUNOTHERAPY; INFLAMMATION MEDIATORS; INTERLEUKINS; MICE; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION;

EID: 84880955619     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2013.06.029     Document Type: Review

References (38)

1. Xu W.D., Liu S.S., Pan H.F., Ye D.Q. Lack of association of TLR4 polymorphisms with susceptibility to rheumatoid arthritis and ankylosing spondylitis: a meta-analysis. Joint Bone Spine 2012, 79:566-569.
2. Fischer S., Agmon-Levin N., Shapira Y., Porat Katz B.S., Graell E., Cervera R., et al. Toxoplasma gondii: bystander or cofactor in rheumatoid arthritis. Immunol Res 2013, 10.1007/s12026-013-8402-2.
3. Ni Mhuircheartaigh O.M., Matteson E.L., Green A.B., Crowson C.S. Trends in serious infections in rheumatoid arthritis. J Rheumatol 2013, 10.3899/jrheum.121075.
4. Mercer L.K., Davies R., Galloway J.B., Low A., Lunt M., Dixon W.G., et al. Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population. Rheumatology (Oxford) 2013, 52:91-98.
5. Yuan F.L., Li X., Lu W.G., Li C.W., Xu R.S., Dong J. IL-33: a promising therapeutic target for rheumatoid arthritis?. Expert Opin Ther Targets 2011, 15:529-534.
6. Collins C.S., Terrell C., Mueller P. Disseminated Mycobacterium haemophilum infection in a 72-year-old patient with rheumatoid arthritis on infliximab. BMJ Case Rep 2013, 10.1136/bcr-2012-008034.
7. Grzegorzewska A.E., Frankiewicz D., Breborowicz D., Matławska I., Bylka W. Disseminated cutaneous Kaposi sarcoma in a patient receiving triptolide/tripdiolide for rheumatoid arthritis. Med Sci Monit 2012, 18:CS67-CS71.
8. Hirano T., Matsuda T., Turner M., Miyasaka N., Buchan G., Tang B., et al. Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur J Immunol 1988, 18:1797-1801.
9. Schoels M.M., van der Heijde D., Breedveld F.C., Burmester G.R., Dougados M., Emery P., et al. Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement. Ann Rheum Dis 2013, 72:583-589.
10. Tada A., Hashida N., Tanaka T., Nishida K. Anti-interleukin-6 receptor antibody therapy-induced retinopathy in a patient with rheumatoid arthritis. Case Rep Rheumatol 2012, 2012:270315.
11. Verri W.A., Souto F.O., Vieira S.M., Almeida S.C., Fukada S.Y., Xu D., et al. IL-33 induces neutrophil migration in rheumatoid arthritis and is a target of anti-TNF therapy. Ann Rheum Dis 2010, 69:1697-1703.
12. Palmer G., Talabot-Ayer D., Lamacchia C., Toy D., Seemayer C.A., Viatte S., et al. Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis. Arthritis Rheum 2009, 60:738-749.
13. Schmitz J., Owyang A., Oldham E., Song Y., Murphy E., McClanahan T.K., et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005, 23:479-490.
14. Palmer G., Gabay C. Interleukin-33 biology with potential insights into human diseases. Nat Rev Rheumatol 2011, 7:321-329.
15. Tago K., Noda T., Hayakawa M., Iwahana H., Yanagisawa K., Yashiro T., et al. Tissue distribution and subcellular localization of a variant form of the human ST2 gene product, ST2V. Biochem Biophys Res Commun 2001, 285:1377-1383.
16. Trajkovic V., Sweet M.J., Xu D. T1/ST2: an IL-1 receptor-like modulator of immune responses. Cytokine Growth Factor Rev 2004, 15:87-95.
17. Hong Y.S., Moon S.J., Joo Y.B., Jeon C.H., Cho M.L., Ju J.H., et al. Measurement of interleukin-33 (IL-33) and IL-33 receptors (sST2 and ST2L) in patients with rheumatoid arthritis. J Korean Med Sci 2011, 26:1132-1139.
18. Talabot-Ayer D., McKee T., Gindre P., Bas S., Baeten D.L., Gabay C., et al. Distinct serum and synovial fluid interleukin (IL)-33 levels in rheumatoid arthritis, psoriatic arthritis and osteoarthritis. Joint Bone Spine 2012, 79:32-37.
19. Cayrol C., Girard J.P. The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc Natl Acad Sci USA 2009, 106:9021-9026.
20. Verri W.A., Guerrero A.T., Fukada S.Y., Valerio D.A., Cunha T.M., Xu D., et al. IL-33 mediates antigen-induced cutaneous and articular hypernociception in mice. Proc Natl Acad Sci USA 2008, 105:2723-2728.
21. Kakkar R., Lee R.T. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov 2008, 7:827-840.
22. Funakoshi-Tago M., Tago K., Hayakawa M., Tominaga S., Ohshio T., Sonoda Y., et al. TRAF6 is a critical signal transducer in IL-33 signaling pathway. Cell Signal 2008, 20:1679-1686.
23. Turnquist H.R., Sumpter T.L., Tsung A., Zahorchak A.F., Nakao A., Nau G.J., et al. IL-1beta-driven ST2L expression promotes maturation resistance in rapamycin-conditioned dendritic cells. J Immunol 2008, 181:62-72.
24. Hamzaoui K., Kaabachi W., Fazaa B., Zakraoui L., Mili Boussen I., Haj Sassi F. Serum IL-33 levels and skin mRNA expression in Behçet's disease. Clin Exp Rheumatol 2013, 1-9.
25. Li X.L., Lin T.T., Qi C.Y., Yuan L., Xia L.P., Shen H., et al. Elevated serum level of il-33 and sst2 in patients with ankylosing spondylitis: associated with disease activity and vascular endothelial growth factor. J Investig Med 2013, [doi: 10.231/JIM.0b013e31828deed2].
26. Xiangyang Z., Lutian Y., Lin Z., Liping X., Hui S., Jing L. Increased levels of interleukin-33 associated with bone erosion and interstitial lung diseases in patients with rheumatoid arthritis. Cytokine 2012, 58:6-9.
27. Matsuyama Y., Okazaki H., Tamemoto H., Kimura H., Kamata Y., Nagatani K., et al. Increased levels of interleukin in sera and synovial fluid from patients with active rheumatoid arthritis. J Rheumaol 2010, 37:18-25.
28. Mu R., Huang H.Q., Li Y.H., Li C., Ye H., Li Z.G. Elevated serum interleukin 33 is associated with autoantibody production in patients with rheumatoid arthritis. J Rheumatol 2010, 37:2006-2013.
29. Kageyama Y., Torikai E., Tsujimura K., Kobayashi M. Involvement of IL-33 in the pathogenesis of rheumatoid arthritis: the effect of etanercept on the serum levels of IL-33. Mod Rheumatol 2012, 22:89-93.
30. Allakhverdi Z., Smith D.E., Comeau M.R., Delespesse G. Cutting edge: the ST2 ligand IL-33 potently activates and drives maturation of human mast cells. J Immunol 2007, 179:2051-2054.
31. Ho L.H., Ohno T., Oboki K., Kajiwara N., Suto H., Iikura M., et al. IL-33 induces IL-13 production by mouse mast cells independently of IgE-FcepsilonRI signals. J Leukoc Biol 2007, 82:1481-1490.
32. Xu D., Jiang H.R., Kewin P., Li Y., Mu R., Fraser A.R., et al. IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc Natl Acad Sci USA 2008, 105:10913-10918.
33. Kunisch E., Chakilam S., Gandesiri M., Kinne R.W. IL-33 regulates TNF-alpha dependent effects in synovial fibroblasts. Int J Mol Med 2012, 29:530-540.
34. Chunxia C., Peng Z., Huifang P., Hanli R., Zehua H., Jizhou W. Extracts of Arisaema rhizomatum C.E.C. Fischer attenuate inflammatory response on collagen-induced arthritis in BALB/c mice. J Ethnopharmacol 2011, 133:573-582.
35. Xu D., Jiang H.R., Li Y., Pushparaj P.N., Kurowska-Stolarska M., Leung B.P., et al. IL-33 exacerbates autoantibody-induced arthritis. J Immunol 2010, 184:2620-2626.
36. Matsuyama Y., Okazaki H., Hoshino M., Onishi S., Kamata Y., Nagatani K., et al. Sustained elevation of interleukin-33 in sera and synovial fluids from patients with rheumatoid arthritis non-responsive to anti-tumor necrosis factor: possible association with persistent IL-1beta signaling and a poor clinical response. Rheumatol Int 2012, 32:1397-1401.
37. Li M., Li Y., Liu X., Gao X., Wang Y. IL-33 blockade suppresses the development of experimental autoimmune encephalomyelitis in C57BL/6 mice. J Neuroimmunol 2012, 247:25-31.
38. Kobori A., Yagi Y., Imaeda H., Ban H., Bamba S., Tsujikawa T., et al. Interleukin-33 expression is specifically enhanced in inflamed mucosa of ulcerative colitis. J Gastroenterol 2010, 45:999-1007.